Subtype
Invasive Prostate Carcinoma
CI-CAN-00002961Explore in graph →
139 active trials1 approved drugs3 evidence items
- NCIt
- C48596
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002961Explore in graph →
Clinical trials
440 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (72)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03456804 | ESK981 in Treating Patients With Metastatic Castrate-Resistant Prostate Cancer | completed | Phase 2 | 13 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Jul 14, 2023 | clinicaltrials |
| NCT04781374 | Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer | withdrawn | Phase 2 | 0 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jul 11, 2023 | clinicaltrials |
| NCT01913717 |
| Short-term High Precision Radiotherapy for Early Prostate Cancer With Concomitant Boost on the Dominant Lesion |
| unknown |
| N/A |
| 65 |
| European Institute of OncologyOTHER |
| 1 |
| Jun 28, 2023 |
| clinicaltrials |
| NCT02672449 | Carbon Ions Boost Followed by Pelvic Photon Radiotherapy for High Risk Prostate Cancer | unknown | N/A | 65 | European Institute of OncologyOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT03553212 | Twice High Dose External Beam Radiotherapy by Image-guided Tomotherapy for Organ-confined Prostate Cancer Treatment Emulating High Dose Radiation (HDR) Brachytherapy(THRIP) | terminated | N/A | 2 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | May 30, 2023 | clinicaltrials |
| NCT01411332 | Hypofractionated Image-Guided Radiotherapy For Prostate Cancer: The HEIGHT Trial(HEIGHT) | completed | N/A | 18 | University of MiamiOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT03535675 | Muscadine Plus (MPX) In Men With Prostate Cancer | terminated | Phase 3 | 59 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT04843319 | To Determine an Effective Dose of VERU-100 for the Treatment of Advanced Prostate Cancer(VERU-100) | terminated | Phase 1 / Phase 2 | 24 | Veru Inc.INDUSTRY | 1 | May 19, 2023 | clinicaltrials |
| NCT05415228 | Expanded Access to Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrent Prostate Cancer | no longer available | — | — | Morand Piert, MDOTHER | 0 | May 18, 2023 | clinicaltrials |
| NCT02058706 | LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer | completed | Phase 2 | 71 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | May 10, 2023 | clinicaltrials |
| NCT03406858 | Pembro and HER2Bi-Armed Activated T Cells in Treating Patients With Metastatic Castration Resistant Prostate Cancer | completed | Phase 2 | 15 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT03368547 | 68Ga-PSMA-11 PET/CT in Imaging Patients With Intermediate or High Risk Prostate Cancer Before Surgery | completed | N/A | 400 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT04085991 | Two TraCer PositROn EmiSSion Tomography ComBination for Efficacy EstimatiOn of Prostate Specific Membrane Antigen Radioligand Therapy in Patients With Metastatic Prostate Cancer(CROSSBOW) | terminated | Phase 2 | 11 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT02624518 | 68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer | completed | Phase 2 / Phase 3 | 122 | Andrei IagaruOTHER | 1 | Apr 10, 2023 | clinicaltrials |
| NCT04976257 | Pharmacokinetics of IA and IV Ga68-PSMA-11 Infusion | completed | Early Phase 1 | 5 | Ryan Kohlbrenner, MDOTHER | 1 | Apr 7, 2023 | clinicaltrials |
| NCT05054296 | Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring | recruiting | Phase 2 | 200 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT02225925 | Intraoperative Dosimetry for Prostate Brachytherapy Using Fluoroscopy and Ultrasound | completed | N/A | 45 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 13, 2023 | clinicaltrials |
| NCT05744115 | Ga-68-PSMA-11 in Men With Prostate Cancer(Ga68-PSMA-11) | terminated | Phase 3 | 38 | Timothy HoffmanFED | 1 | Feb 24, 2023 | clinicaltrials |
| NCT02721979 | Apalutamide in Treating Patients With Prostate Cancer Who Are in Active Surveillance | terminated | Phase 2 | 24 | University of WashingtonOTHER | 1 | Feb 9, 2023 | clinicaltrials |
| NCT03982173 | Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors(MATILDA) | withdrawn | Phase 2 | 0 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 0 | Jan 26, 2023 | clinicaltrials |
| NCT01856855 | Pilot Trial Evaluating Stereotactic Body Radiotherapy With Integrated Boost for Clinically Localized Prostate Cancer (RAD 1203) | completed | N/A | 26 | John Fiveash, MDOTHER | 1 | Jan 12, 2023 | clinicaltrials |
| NCT02454517 | Diet and Exercise Program to Promote Weight Loss and Improve Health in Men With Low- or Low-Intermediate-Risk Prostate Cancer(PALS) | terminated | N/A | 117 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 4, 2023 | clinicaltrials |
| NCT02446366 | Hypofractionated Stereotactic Body Radiation Therapy for Patients With Prostate Cancer That Was Removed by Surgery | unknown | N/A | 24 | University of Southern CaliforniaOTHER | 1 | Dec 12, 2022 | clinicaltrials |
| NCT04638049 | Intestinal Microbiota in Prostate Cancer Patients as a Biomarker for Radiation-INduced Toxicity (IMPRINT)(IMPRINT) | completed | N/A | 50 | University Hospital, GhentOTHER | 1 | Dec 1, 2022 | clinicaltrials |
| NCT05589558 | Prospective Comparison of the Four Biopsy Methods for Prostate Cancer Detection | completed | N/A | 102 | I.M. Sechenov First Moscow State Medical UniversityOTHER | 1 | Oct 21, 2022 | clinicaltrials |
| NCT05573789 | Tumor Molecular Profiling in Patients With Prostate Cancer | completed | — | 220 | Hellenic Cooperative Oncology GroupOTHER | 1 | Oct 19, 2022 | clinicaltrials |
| NCT02064036 | Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate(CCRO025) | completed | Phase 1 | 17 | University of California, DavisOTHER | 1 | Oct 18, 2022 | clinicaltrials |
| NCT01174199 | Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer | terminated | Phase 1 | 13 | Roswell Park Cancer InstituteOTHER | 1 | Oct 3, 2022 | clinicaltrials |
| NCT04946214 | A Behavioral Health Intervention Using Digital Technology in Radiation Therapy for Prostate Cancer Patients(HIDRATEPRO) | completed | N/A | 18 | University of MiamiOTHER | 1 | Sep 30, 2022 | clinicaltrials |
| NCT04685811 | Evaluation of PSMA Antagonist Produced by Two Different Methods | completed | Phase 1 / Phase 2 | 16 | Weill Medical College of Cornell UniversityOTHER | 1 | Sep 22, 2022 | clinicaltrials |
| NCT03279250 | Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer | completed | Phase 2 | 86 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2022 | clinicaltrials |
| NCT04331717 | Bariatric Arterial Embolization for Men Starting Hormones for Prostate Cancer(BASH-PC) | withdrawn | Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 2, 2022 | clinicaltrials |
| NCT04033432 | sEphB4-HSA in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | unknown | Phase 2 | 14 | Northwestern UniversityOTHER | 1 | Apr 27, 2022 | clinicaltrials |
| NCT02268175 | Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate | completed | Phase 2 | 75 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 19, 2022 | clinicaltrials |
| NCT04221828 | Trial of NanoPac Focal Therapy for Prostate Cancer | terminated | Phase 2 | 1 | NanOlogy, LLCINDUSTRY | 1 | Mar 29, 2022 | clinicaltrials |
| NCT02678351 | 68Ga-PSMA-11 PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery | completed | Phase 2 / Phase 3 | 74 | Andrei IagaruOTHER | 1 | Mar 4, 2022 | clinicaltrials |
| NCT05224024 | Retzius-sparing Technique in Robotic-assisted Radical Prostatectomy | unknown | N/A | 80 | Ankara UniversityOTHER | 1 | Feb 4, 2022 | clinicaltrials |
| NCT02601014 | Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7(STARVE-PC) | completed | Phase 2 | 32 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 3, 2022 | clinicaltrials |
| NCT03501940 | F18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate Cancer | no longer available | — | — | Andrei IagaruOTHER | 1 | Jan 21, 2022 | clinicaltrials |
| NCT02673151 | 68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment | completed | Phase 2 / Phase 3 | 61 | Andrei IagaruOTHER | 1 | Jan 13, 2022 | clinicaltrials |
| NCT02849990 | A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy | completed | Phase 2 | 22 | University of WashingtonOTHER | 1 | Jan 13, 2022 | clinicaltrials |
| NCT00887432 | Cholecalciferol Supplement in Treating Patients With Localized Prostate Cancer Undergoing Observation | completed | N/A | 132 | Roswell Park Cancer InstituteOTHER | 1 | Oct 26, 2021 | clinicaltrials |
| NCT04050215 | 68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer | completed | Phase 2 | 937 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Sep 30, 2021 | clinicaltrials |
| NCT04020094 | Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And High-Risk Localized Prostate Cancer(AtezoVax) | withdrawn | Phase 2 | 0 | University of UtahOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT05022914 | PSMA Guided Approach for bIoCHEmical Relapse After Prostatectomy-PSICHE(PSICHE) | recruiting | — | 180 | Azienda Ospedaliero-Universitaria CareggiOTHER | 1 | Aug 26, 2021 | clinicaltrials |
| NCT01812668 | Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer | completed | N/A | 20 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Aug 5, 2021 | clinicaltrials |
| NCT03829930 | Combination of Entinostat and Enzalutamide in Advanced Prostate Cancer | terminated | Phase 1 | 6 | George Washington UniversityOTHER | 1 | Aug 2, 2021 | clinicaltrials |
| NCT01505868 | Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 170 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2021 | clinicaltrials |
| NCT04146077 | Active Surveillance for Low Risk Prostate Cancer | recruiting | — | 100 | I.M. Sechenov First Moscow State Medical UniversityOTHER | 1 | Jul 22, 2021 | clinicaltrials |
| NCT04192890 | Efficacy and Safety Assessment of IRE of Localized Prostate Cancer | unknown | N/A | 12 | I.M. Sechenov First Moscow State Medical UniversityOTHER | 1 | Jul 22, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Jul 14, 2023source: clinicaltrials